Neptune Medical Announces $97M Series D Financing and Spinout of Jupiter Endovascular
2024年8月15日 - 9:00PM
ビジネスワイヤ(英語)
Neptune Medical, a leader in medical device innovation, today
announced the successful spinout of its subsidiary, Jupiter
Endovascular, following the completion of a $97 million Series D
financing. Sonder Capital and Olympus Corporation of the Americas
were significant participants in this round, along with investments
from other existing and new investors.
This financing will strengthen Neptune Medical as a
gastrointestinal-focused company expanding into robotics for GI
disease, as evidenced by the recent appointment of medical robotics
pioneer Dr. Fred Moll as Chairman of the Board. It will also enable
Jupiter Endovascular to focus on its novel endovascular technology
platform.
"Neptune Medical is thrilled to announce the successful closure
of our Series D financing and the spinout of Jupiter Endovascular.
These significant milestones allow us to sharpen our focus on GI
robotics while empowering Jupiter to drive innovation in
endovascular treatments," said Alex Tilson, Founder and CEO of
Neptune Medical. "We are grateful to our investors for their
unwavering support and confidence in our vision."
Dr. Moll commented, "The spinout of Jupiter Endovascular is a
strategic move that aligns with our long-term goals. With dedicated
resources and leadership, Jupiter is well-positioned to
revolutionize endovascular therapies. Meanwhile, Neptune will
continue to push the boundaries in GI robotics, delivering
transformative solutions to patients and healthcare providers. We
intend for both companies to lead the way in innovating within
their respective specialties."
Chief Strategy Officer for Olympus, Gabriela Kaynor, added, "We
are excited to participate in this financing round for Neptune
Medical. We believe Neptune's innovative approach to endoscopy has
the potential to elevate the standard of care by improving patient
outcomes."
About Neptune Medical
Neptune Medical is at the forefront of developing advanced
medical devices, with a primary focus on gastrointestinal robotics.
The company's mission is to enhance patient outcomes through
innovative technology and collaborative partnerships.
About Jupiter Endovascular
Jupiter Endovascular, a spinout of Neptune Medical, is
developing a new class of endovascular procedures to bring the
precision and control of direct surgical access to catheter-based
interventions.
About Olympus Corporation
At Olympus, we are committed to Our Purpose of making people’s
lives healthier, safer and more fulfilling. As a global medical
technology company, we partner with healthcare professionals to
provide best-in-class solutions and services for early detection,
diagnosis and minimally invasive treatment, aiming to improve
patient outcomes by elevating the standard of care in targeted
disease states.
For more than 100 years, Olympus has pursued a goal of
contributing to society by producing products designed with the
purpose of delivering optimal outcomes for its customers around the
world.
For more information, visit www.olympus-global.com and follow
our global X account: @Olympus_Corp.
About Sonder Capital
Sonder’s team of veteran investors, innovators,
founder-operators, and company builders is known not only for their
individual achievements, but also for their collective success in
creating, funding, and leading private and public companies that
have transformed healthcare for millions of patients globally —
including Intuitive Surgical (NASDAQ:ISRG), Procept Biorobotics
(NASDAQ:PRCT), Shockwave Medical, Auris Health, and Reflexion
Medical, among others. Sonder’s extensive network of limited
partners is global and includes industry leaders, high-net-worth
individuals, and leading family offices focused on investing in
game-changing healthcare technologies. Sonder Capital was
co-founded in 2019 by healthcare luminaries Jay Watkins and Fred
Moll, M.D.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240815402386/en/
MEDIA CONTACT: Michelle McAdam, Chronic Communications,
Inc. michelle@chronic-comm.com, (310) 902-1274